Correlation between the Warburg effect and progression of triple-negative breast cancer

被引:14
|
作者
Liu, Shaojun [1 ]
Li, Yuxuan [1 ]
Yuan, Meng [1 ]
Song, Qing [1 ]
Liu, Min [1 ]
机构
[1] Nanjing Univ Chinese Med, Dept Oncol, Suzhou TCM Hosp, Suzhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 12卷
基金
中国国家自然科学基金;
关键词
Warburg effect; glycolysis; metabolic plasticity; triple-negative breast cancer; basal-like breast cancer; METABOLIC PATHWAYS; CELL COMPETITION; DRUG-RESISTANCE; TUMOR DORMANCY; METASTASIS; MECHANISMS; INHIBITION; PROMOTES; CYCLE; ACTIVATION;
D O I
10.3389/fonc.2022.1060495
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer (TNBC) is ineligible for hormonal therapy and Her-2-targeted therapy due to the negative expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2. Although targeted therapy and immunotherapy have been shown to attenuate the aggressiveness of TNBC partially, few patients have benefited from them. The conventional treatment for TNBC remains chemotherapy. Chemoresistance, however, impedes therapeutic progress over time, and chemotherapy toxicity increases the burden of cancer on patients. Therefore, introducing more advantageous TNBC treatment options is a necessity. Metabolic reprogramming centered on glucose metabolism is considered a hallmark of tumors. It is described as tumor cells tend to convert glucose to lactate even under normoxic conditions, a phenomenon known as the Warburg effect. Similar to Darwinian evolution, its emergence is attributed to the selective pressures formed by the hypoxic microenvironment of pre-malignant lesions. Of note, the Warburg effect does not disappear with changes in the microenvironment after the formation of malignant tumor phenotypes. Instead, it forms a constitutive expression mediated by mutations or epigenetic modifications, providing a robust selective survival advantage for primary and metastatic lesions. Expanding evidence has demonstrated that the Warburg effect mediates multiple invasive behaviors in TNBC, including proliferation, metastasis, recurrence, immune escape, and multidrug resistance. Moreover, the Warburg effect-targeted therapy has been testified to be feasible in inhibiting TNBC progression. However, not all TNBCs are sensitive to glycolysis inhibitors because TNBC cells flexibly switch their metabolic patterns to cope with different survival pressures, namely metabolic plasticity. Between the Warburg effect-targeted medicines and the actual curative effect, metabolic plasticity creates a divide that must be continuously researched and bridged.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Advanced Triple-Negative Breast Cancer
    Patel, Grisma
    Prince, Alison
    Harries, Mark
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [32] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [33] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805
  • [34] Pembrolizumab in Triple-Negative Breast Cancer
    Altundag, Kadri
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1436
  • [35] A Review of Triple-Negative Breast Cancer
    Ismail-Khan, Roohi
    Bui, Marilyn M.
    CANCER CONTROL, 2010, 17 (03) : 173 - 176
  • [36] Triple-negative breast cancer: an update
    Boolbol, Susan K.
    Cate, Sarah P.
    BREAST CANCER MANAGEMENT, 2014, 3 (02) : 127 - 129
  • [37] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [38] Morphotypes of the triple-negative breast cancer
    Koleckova, M.
    Kolar, Z.
    Ehrmann, J.
    Korinkova, G.
    Trojanec, R.
    VIRCHOWS ARCHIV, 2017, 471 : S296 - S296
  • [39] Pembrolizumab for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2020, 21 (04): : E183 - E183
  • [40] Targeting triple-negative breast cancer
    Peter Kirkpatrick
    Nature Reviews Drug Discovery, 2009, 8 : 21 - 21